GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Ribociclib tablets (Kisqali)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Kisqali - selected RX renal passage

Product / population
Ribociclib (Kisqali), oral tablets for adult breast cancer
Renal method
Use the renal measure explicitly present in the RX passage.
Source revision
Mirror revision not established in the reviewed passage.
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Kisqali - product and source limitations

The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.

What to reconcile: The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Rxlist

Kisqali - selected RX renal passage

Open original reference

GlobalRPh RX List / product-label mirror · Ribociclib (Kisqali), oral tablets for adult breast cancer

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror specifies a lower starting dose of 200 mg on treatment days in severe impairment.

RDM73-kisqali-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/kisqali-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
7a9853c62eb2f6119656763fee78c6e848e5d3d327f4480a9287702538c00fd2

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ribociclib-kisqali&s1=RDM73-kisqali-rxlist&h1=eef702bc1eda133dd0629c75e612feb556bbb0cf23f009b37f848033aba2b21c

Top